0001144204-19-045474.txt : 20191023 0001144204-19-045474.hdr.sgml : 20191023 20190920163202 ACCESSION NUMBER: 0001144204-19-045474 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20190920 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABEONA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000318306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 830221517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1330 AVENUE OF THE AMERICAS, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 646-813-4701 MAIL ADDRESS: STREET 1: 1330 AVENUE OF THE AMERICAS, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: PLASMATECH BIOPHARMACEUTICALS INC DATE OF NAME CHANGE: 20140922 FORMER COMPANY: FORMER CONFORMED NAME: ACCESS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960209 FORMER COMPANY: FORMER CONFORMED NAME: CHEMEX PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

 

 

 

Christine Silverstein

Chief Financial Officer

Abeona Therapeutics Inc.
1330 Avenue of the Americas, 33rd Floor
New York, NY 10019

 

September 20, 2019

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Healthcare & Insurance

100 F Street, N.E.

Washington, D.C. 20549

 

Attention:Mary Mast

Angela Connell

 

Re:Abeona Therapeutics Inc.

Form 10-K for the Fiscal Year Ended December 31, 2018

Filed March 18, 2019

File No. 001-15771

 

Ladies and Gentlemen:

 

Abeona Therapeutics Inc. (the “Company”) submits this letter in response to your letter dated September 17, 2019, relating to the above-referenced filing by the Company. Set forth below in italics is the comment contained in the Staff’s letter, together with the Company’s response. Capitalized terms not defined herein should be given the meaning provided in the above-referenced filing.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Contractual Obligations, page 61

 

1.Refer to your response to our prior comment 1 and your disclosure in your Form 10-Q for the quarterly period ended June 30, 2019. The revised disclosure in Note 4 of the Form 10-Q relating to royalties in the low double digits to low teens does not appear to be limited to within a 10 point range. Please confirm that you will revise your future filings to disclose the royalty rate or range that does not exceed a 10 point range.

 

Response: In response to the Staff’s comment, we respectfully inform that we believe the disclosure in Note 4 of the Form 10-Q for the period ended June 30, 2019 is limited to within a 10 point range. The reference to “low double digits to low teens” in our disclosure indicates that “low double digits” is the low end of the range and “low teens” is the high end of the range. As such, the high and low ends of the range are within 10 points of each other. We thus respectfully request that the Staff agree with our position that further revision to our disclosure in future filings is not necessary.

 

 

1330 Avenue of the Americas – Floor 33, New York, New York 10019

Tel 1-646-813-4707 • www.abeonatherapeutics.com

 

 

 

 

 

If you have any questions regarding this response letter or the Form 10-K, please contact our counsel, Morgan, Lewis & Bockius LLP, by calling John J. Concannon III at (617) 951-8874.

 

  Very truly yours,
  ABEONA THERAPEUTICS INC.
 

 

By:

 

/s/ Christine Silverstein

  Name: Christine Silverstein
  Title: Chief Financial Officer
     

 

CC:John J. Concannon III, Esq., Morgan, Lewis & Bockius LLP

 

 

 

 

 

 

 

 

 

 

 

1330 Avenue of the Americas – Floor 33, New York, New York 10019

Tel 1-646-813-4707 • www.abeonatherapeutics.com

 

 GRAPHIC 2 logo.gif GRAPHIC begin 644 logo.gif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end